This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	CC chemokine receptor 2 (CCR2; CD192); monocyte chemoattractant protein-1 (MCP-1; CCL2)	Studies in patient samples and mice suggest depleting *CCR2*$^+$ inflammatory monocytes could help treat intracerebral hemorrhage. Mice subjected to intracerebral hemorrhage showed higher levels of *Ccr2*$^+$ inflammatory monocytes than sham-operated controls. In patient serum samples, high levels of the CCR2 ligand CCL2 were associated with increased disability and risk of death following intracerebral hemorrhage. In mice, treatment with an anti-CCR2 antibody decreased motor deficits following intracerebral hemorrhage compared with an isotype control antibody. Next steps include evaluating how depletion of inflammatory monocytes affects long-term outcomes after intracerebral hemorrhage and susceptibility to infections. At least six companies have CCR2-inhibiting compounds in Phase II or earlier testing for various conditions outside of neurology. *SciBX* 7(13); doi:10.1038/scibx.2014.379 Published online April 3, 2014	Unpatented; licensing status not applicable	Hammond, M.D. *et al. J. Neurosci.*; published online March 12, 2014; doi:10.1523/JNEUROSCI.4070-13.2014 **Contact:** Lauren Sansing, University of Connecticut Health Center, Farmington, Conn. e-mail: sansing@uchc.edu